A review of novel biomarkers and imaging techniques for assessing the severity of chemotherapy-induced peripheral neuropathy.
Paola AlbertiPublished in: Expert opinion on drug metabolism & toxicology (2020)
At the present moment, neuroimaging and biomarkers are not yet part of the clinical practice for CIPN management, but they deserved to be tested since they could be a valuable surrogate endpoint in a clinical trial. To ascertain the appropriateness of (a) potential biomarker(s), it is crucial to design a clinical trial based on sound design and taking advantage of international, multidisciplinary initiatives, such as the Toxic Neuropathy Consortium.